Creatgroup: China's Creat suffers setback in Biotest deal on US scrutiny

FRANKFURT: Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro (US$1.51-billion) takeover of Biotest , the German blood plasma products maker said, sending its shares sharply lower. The Committee on Foreign Investment in the United States ...